U.S. Investments Drive First Annual Increase In Funding For Neglected Diseases Research Since 2012, G-FINDER Report Shows
Devex: R&D for neglected diseases reliant on just two donors, G-FINDER report warns
“…The G-FINDER report, released on Wednesday, tracks investments in drugs, vaccines, diagnostics, microbicides, and vector control products and also basic research across 33 neglected diseases — a group of diseases that lead to approximately 6.4 million deaths per year and disproportionately affect people in developing countries. A smaller commercial market means the diseases typically struggle to attract sufficient research and development. The 10th edition of the report, funded by the Bill & Melinda Gates Foundation, revealed that between 2015 and 2016, $3.2 billion was invested in neglected disease R&D — an increase of 3.4 percent on the previous year, and the first annual increase since 2012…” (Edwards, 12/14).
Intellectual Property Watch: G-FINDER Report: Global Funding For R&D In Neglected Diseases Increasing, Overreliance On U.S. Funding Dangerous
“A report released [Wednesday] on global funding of research and development for neglected diseases found that global funding has increased but warns that overreliance on funding from the United States, which the report says is ‘unparalleled,’ and leads to a heavy concentration of global funding on HIV/AIDS, malaria, and tuberculosis. This overreliance could also lead to change in total global funding, the report found…” (Saez, 12/13).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.